Globe Newswire (Thu, 26-Mar 4:05 PM ET)
Globe Newswire (Wed, 18-Mar 4:05 PM ET)
Market Chameleon (Tue, 21-Oct 7:08 AM ET)
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Spero Therapeutics trades on the NASDAQ stock market under the symbol SPRO.
As of April 22, 2026, SPRO stock price climbed to $2.88 with 212,704 million shares trading.
SPRO has a beta of 0.36, meaning it tends to be less sensitive to market movements. SPRO has a correlation of 0.00 to the broad based SPY ETF.
SPRO has a market cap of $166.73 million. This is considered a Micro Cap stock.
In the last 3 years, SPRO traded as high as $3.22 and as low as $.51.
The top ETF exchange traded funds that SPRO belongs to (by Net Assets): VTI, VXF, QQQS, AVSC, DFAS.
SPRO has outperformed the market in the last year with a price return of +297.2% while the SPY ETF gained +39.5%. SPRO has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +22.0% and +7.9%, respectively, while the SPY returned +3.8% and +7.6%, respectively.
SPRO support price is $2.69 and resistance is $2.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SPRO shares will trade within this expected range on the day.
